ECEESPE2025 ePoster Presentations Endocrine Related Cancer (100 abstracts)
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs): clinical profile, treatment and 10-year survival
Fernando Vidal-Ostos De Lara 1 , Jose Ignacio Busteros Moraza 2 , Remedios Gomez Sanz 3 , Bernard Theillac 4 , Raquel Niddam Sanchez 1 , Edinson Caviedes Sanchez 5 , María Laura Villalobos Leon 5 & Concepción Blanco 1
1Principe de Asturias University Hospital, Endocrinology and nutrition, Alcalá de Henares (Madrid)., Spain; 2Principe de Asturias University Hospital, Pathological anatomy, Alcalá de Henares (Madrid)., Spain; 3Principe de Asturias University Hospital, General surgery, Alcalá de Henares (Madrid)., Spain; 4Principe de Asturias University Hospital, Nuclear medicine, Alcalá de Henares (Madrid)., Spain; 5Principe de Asturias University Hospital, Oncology, Alcalá de Henares (Madrid)., Spain
JOINT2561
Introduction: GEP-NETs are rare and heterogeneous neoplasms. Its prognosis depends on the histological grade as well as the extent of the tumour.
Material and Methods: We present a retrospective descriptive study based on patients diagnosed of GEP-NET and treated in a multidisciplinary unit in the last 10 years. Demographic data, location, tumour grade, metastases, treatment and survival were collected.
Results: From january 2014 to December 2024, 134 patients were diagnosed of GEP-NET. The annual incidence was 6.47 cases per 100,000 population and the adjusted prevalence was 0.052%. The mean age at diagnosis was 58+15 years, 51% were men and 49 % women. The most common origin was the pancreas (52%), followed by the jejunum-ileum (23%). At diagnosis 24% had distant metastases, most often located in the liver (44 %), peritoneum (25%) or multiple organs (22%). Most of them were sporadic and non-functional. Only 27 tumors were functional, most common insulinomas (11) and 10 had an inherited syndrome (9 MEN1 and 1 NF1). 66 % of patients underwent surgery for the primary tumour. The histological grade was G1 73%, G2 22% and G3 5%. 47 patients had tumour persistence and received somatostatin analogues (47), liver-directed therapy (11), systemic treatments such as everolimus (20), sunitinib (5), chemotherapy (7) and lutetium (12). During the follow up 26% of patients died. 74% were alive at the time of the last visit. The mean survival after diagnosing was 6 + 5 years (median 5 years). At last visit 44% of patients had complete remission 2.4% partial response, 30.5% stable disease and 23% progression.
Conclusions: The incidence of GEP-NETs is higher than previous reports probably related to greater diagnostic resources. GEP-NETs have a relatively long survival even in those with metastases. Early diagnosis and multimodal treatment improve survival.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more